Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Pembrolizumab plus chemoradiotherapy significantly improves survival in high-risk cervical cancer patients.